Altretamine (hydrochloride)

Altretamine hydrochloride is an alkylating antineoplastic agent.

Signaling Pathways >> Cell Cycle/DNA Damage >> DNA Alkylator/Crosslinker

Research Areas >> Cancer

Altretamine hydrochloride is an antineoplastic agent[1].

Altretamine (100, 133 mg/kg, ip.) in combination with Irofulven, increases the antitumor effect in mice bearing MV522 cells[1].

Mice[1] Balb/c nu/nu 4 week old female mice weighing 18-22 g, receive s.c. injections of 8-10 million MV522 cells. Altretamine is administered i.p. three times a week for 3 weeks, starting on day 10 after tumor implantation. Tumor size is measured in two perpendicular diameters and tumor weight (TW) estimated according to the formula: w = [(width)2 × length/2]. Altretamine is prepared as stock solutions of 1-10 mg/mL in 40% DMSO/normal saline and diluted with 10% DMSO/normal saline as required[1].

[1]. Kelner MJ, et al. Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model. Cancer Chemother Pharmacol. 2008 Dec;63(1):19-26.

Calicheamicin | Carmustine | RITA (NSC 652287) | Lomustine | SJG-136 | Fotemustine | Procarbazine hydrochloride | Thio-TEPA | VAL-083 | Miriplatin | Altretamine | Treosulfan | Uramustine | Satraplatin